Rachel A. Hoffman

Rachel A. Hoffman

Auto-generated profile, based on publicly available information

Rachel A. Hoffman

Nationwide Children’s Hospital 2 Center for Childhood Cancer Research Columbus, Ohio

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2021 in Genes & Development
Verified
Journal Article
Open access
PDF file
RHRachel A. Hoffman
Rachel A. Hoffman
HMHeather K. MacAlpine
Heather K. MacAlpine
DMDavid M. MacAlpine
David M. MacAlpine
Prior to initiation of DNA replication, the eukaryotic helicase, Mcm2-7, must be activated to unwind DNA at replication start sites in early S phase. To study helicase activation within origin chromatin, we constructed a conditional mutant of the polymerase α subunit Cdc17 (or Pol1) to prevent priming and block replication. Recovery of these cells at permissive conditions resulted in the generation of unreplicated gaps at origins, likely due to helicase activation prior to replication initiation. We used micrococcal nuclease (MNase)-based chromatin occupancy profiling under restrictive conditions to study chromatin dynamics associated with helicase activation. Helicase activation in the absence of DNA replication resulted in the disruption and disorganization of chromatin, which extends up to 1 kb from early, efficient replication origins. The CMG holohelicase complex also moves the same distance out from the origin, producing single-stranded DNA that activates the intra-S-phase checkpoint. Loss of the checkpoint did not regulate the progression and stalling of the CMG complex but rather resulted in the disruption of chromatin at both early and late origins. Finally, we found that the local sequence context regulates helicase progression in the absence of DNA replication, suggesting that the helicase is intrinsically less processive when uncoupled from replication.

21 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
RHRachel A. Hoffman
Rachel A. Hoffman
MWMeng Wang
Meng Wang
BSBenjamin D. Sunkel
Benjamin D. Sunkel
TNThanh Hung Nguyen
Thanh Hung Nguyen
JLJorge Lopez-Nava
Jorge Lopez-Nava
BSBenjamin Stanton
Benjamin Stanton
In the fusion-positive subset of rhabdomyosarcoma, the PAX3::FOXO1 oncoprotein is the most common fusion driver. We previously established a human myoblast system for inducible expression of PAX3::FOXO1. In the current study, we modulate PAX3::FOXO1 protein expression to understand the epigenetic and phenotypic functions at different PAX3::FOXO1 levels. Proliferative and oncogenic outcomes depend on PAX3::FOXO1 dosage in this system with transformation dominant at intermediate levels and growth suppression dominant at high levels. After prolonged PAX3::FOXO1 expression, there is dosage-dependent heterogeneity in single cell gene expression profiles. We observe a dosage-specific effect for PAX3::FOXO1 chromatin recognition and identify factors that modulate PAX3::FOXO1 chromatin binding. PAX3::FOXO1 dosage affects expression signatures related to cell cycle, epithelial-mesenchymal transition, and myogenesis. Whereas intermediate PAX3::FOXO1 expression maximizes chromatin binding to modulate gene expression, high PAX3::FOXO1 expression alters S phase progression and increases accessibility behind the replication fork. We conclude that PAX3::FOXO1 exerts dosage-dependent functions to influence epigenetic heterogeneity in fusion-positive rhabdomyosarcoma.

19 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
ATAlexi Tallan
Alexi Tallan
JKJack Kucinski
Jack Kucinski
AVAndrew M. Vontell
Andrew M. Vontell
CKChamithi Karunanayake
Chamithi Karunanayake
RHRachel A. Hoffman
Rachel A. Hoffman
BSBenjamin Stanton
Benjamin Stanton
SUMMARY: Fusion positive rhabdomyosarcoma (FP-RMS) is an aggressive soft-tissue sarcoma that most frequently affects children and adolescents. Treatment options and outcomes for children with this cancer remain poor, non-specific, and broadly toxic despite decades of research. The defining molecular drivers of the more aggressive fusion-positive subtype of the disease arise from chromosomal translocations that fuse PAX3 or PAX7 to FOXO1 to form PAX3::FOXO1 or PAX7::FOXO1, encoding fusion oncoprotein transcription factors. Despite their high degree of similarity, PAX3::FOXO1 correlates with worse patient overall survival than PAX7::FOXO1 . Previous work from our groups and others has revealed evidence focused in chromatin accessibility contexts that PAX3::FOXO1 has key characteristics of a pioneer transcription factor, a specialized subclass of transcription factors that can bind nucleosomal DNA prior to generation of local accessibility. However, evidence at the genome scale for PAX3/7::FOXO1 direct nucleosome targeting, prior to the accessibility step in pioneering, has remained elusive and challenging to capture methodologically for RMS fusion oncoproteins. In this work, we compare the cellular functions of these PAX::FOXO1 fusions, including new approaches for identifying nucleosome targeting at the genome scale. We find that in zebrafish RMS initiation models, the fusions initially activate similar neural transcriptional programs but to different extents, and we further evaluate their mechanisms in RMS cells at the genome scale with modified MNase XChIP to detect nucleosome and subnucleosome fusion/chromatin binding. In establishing our cross-species comparative oncology approach, we report, to our knowledge, the first high resolution nucleosome positioning data in rhabdomyosarcoma. We find that both PAX::FOXO1 fusions bind nucleosomal DNA, but with varied motif preferences and histone mark co-localization patterns. Altogether, we establish the nucleosome targeting functions of PAX7::FOXO1 and PAX3::FOXO1 pioneering and uncover key mechanistic distinctions for chromatin engagement of the two most common RMS fusion oncoproteins. HIGHLIGHTS: Partially overlapping gene signatures are activated by PAX3/7::FOXO1 in vivo Modified MNase ChIP reveals PAX3/7::FOXO1 bind nucleosomal and subnucleosomal DNA PAX7::FOXO1 binds degenerate paired/homeobox motifs within nucleosome targets Each fusion engages distinct nucleosomal gene targets

27 February 2023 in Biochemistry
Verified
Journal Article
Closed access
ATAlexi Tallan
Alexi Tallan
RHRachel A. Hoffman
Rachel A. Hoffman
BSBenjamin Stanton
Benjamin Stanton

3 November 2026
Verified
Other
Open access
PDF file
SZShabir Zargar
Shabir Zargar
PRPawan Kumar Raut
Pawan Kumar Raut
HKHana Kim
Hana Kim
SBSalah Boudjadi
Salah Boudjadi
RHRachel A. Hoffman
Rachel A. Hoffman
FBFrederic G. Barr
Frederic G. Barr
Clonogenic assay of Dbt-MYCN-iP3F subclones with and without targeted deletion of distal P3F-binding site.